19 results about "Beta-boswellic acid" patented technology

The invention discloses a joint health-care tablet based on glucosamine hydrochloride and sodium chondroitin sulfate and a preparation method, and relates to the technical field of medical health care. The joint health-care tablet comprises the following components: glucosamine hydrochloride, sodium chondroitin sulfate, a frankincense extract, an aesculus chinensis extract, microcrystalline cellulose, povidone, croscarmellose sodium and silicon dioxide. Through scientific proportioning of various active components such as the glucosamine hydrochloride, the chondroitin sulfate sodium, the frankincense extract and the aesculus chinensis extract, comprehensive protection of joint health is realized, the glucosamine hydrochloride and the chondroitin sulfate sodium are used as basic components, repair and regeneration of articular cartilage are promoted, and the joint health is improved. Boswellic acid compounds in the frankincense extract and aescin in the aesculus chinensis extract have anti-inflammatory and analgesic effects and can effectively relieve arthralgia and inflammation, multiple effects are synergistic, and the joint health care effect is improved.

The application discloses a carbonyl reductase mutant, a combined enzyme and application of the combined enzyme in synthesis of S-configuration boselike, and belongs to the technical field of biological catalysis and pharmacy. The amino acid sequence of the wild-type carbonyl reductase mutant provided by the application is shown as SEQ ID NO:1, and the mutant is obtained by mutation of the wild-type carbonyl reductase, and the mutation mode is that F at the 147th position is mutated into L, V at the 163rd position is mutated into Y, L at the 176th position is mutated into E, and P at the 200th position is mutated into R. By using the mutant, a catalytic system is formed by combining the mutant with formic acid dehydrogenase (FDH), and optical pure S-configuration boselike can be efficiently and highly selectively prepared under high substrate concentration of 250-320 g / L, separation and purification problems caused by generation of a large amount of soluble by-products in catalysis of other combined enzymes are avoided, a post-treatment process is obviously simplified, and production cost and environmental burden are reduced.

The present disclosure relates to a skin care composition comprising boswellic acids and vitamin B12 or derivatives thereof. The compositions can be advantageously used in a method of treatment of dermatological conditions, disorders or diseases, in particular psoriasis, more particularly plaque psoriasis.

The present invention discloses water-soluble 3-O-acetyl-11-keto-β-boswellic acid compositions comprising 3-O-acetyl-11-keto-β-boswellic acid in combination with a metal ion selected from potassium or sodium in the form of respective metal salt or complex or chelate; process for their preparation; methods of prevention, control and / or treatment of at least one disorder selected from muscle soreness, delayed-onset of muscle soreness (DOMS), muscles tenderness, muscle pain, muscle fatigue, muscle sprain, temporary loss of muscle strength and swelling in muscles.

Compositions are described including a synergistic combination of hydroxytyrosol and 3-0-acetyl-11-keto-B-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-0-acetyl-11-keto-B-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof. 20 25 20 28 75 23 A pr 2 02 5 2 4 4 2 0 6 7 4 . 1 : D C C 3 1 / 0 5 / 2 0 2 3 C O M P O S I T I O N S C O M P R I S I N G H Y D R O X Y T Y R O S O L A N D B O S W E L L I C A C I D 2 0 2 5 2 0 2 8 7 5 2 3 2 0 2 5 A p r A B S T R A C T

The invention provides an application of beta-masticinic acid in preparation of a medicine with a tumor immune microenvironment regulating effect. According to the new application of the beta-masticinic acid, the targeting property is clear, the beta-masticinic acid directly regulates and controls Kyn metabolism, the complexity of multiple components of the western huang pill is avoided, and quality control and dosage standardization are facilitated; in an in-vitro experiment, the beta-masticinic acid (100 mu M) has the most remarkable tumor cell proliferation inhibition effect, and the beta-masticinic acid (100 mu M) remarkably reduces the Kyn expression level of macrophages and remarkably enhances the expression of M1 type macrophages; the beta-masticinic acid can play a role in regulating a tumor immune microenvironment through an ERBB2 target spot; the safety is high: the beta-masticinic acid has an anti-tumor effect by regulating immune cells under an effective dose, while the traditional chemotherapeutic drug gemcitabine causes immune injury; the mechanism is novel, and it is found for the first time that beta-masticinic acid regulates the tumor immune microenvironment by influencing the expression of Kyn.

The invention relates to the field of plant volatile oil, and discloses plant volatile oil with a broad-spectrum bactericidal effect and a preparation method thereof.The plant volatile oil with the broad-spectrum bactericidal effect is prepared from a plant volatile oil slow-release compound, menthol, vitamin E succinic acid ester, sodium dodecyl sulfate, sodium dodecyl sulfate and sodium dodecyl sulfate. The plant volatile oil slow-release compound is prepared by grafting aminated mesoporous zinc oxide prepared by a solvothermal method with masticinic acid, then loading plant volatile oil on the obtained masticinic acid grafted mesoporous zinc oxide and taking the plant volatile oil as a core material, and then preparing the plant volatile oil slow-release compound by taking hydroxypropyl-beta-cyclodextrin as a wall material. The preparation method comprises the following steps: carrying out water bath clathration to form a clathrate compound, carrying out hydrophobic modification on the surface of the clathrate compound by using n-octylene succinic anhydride, and finally mixing the modified clathrate compound, choline-lactic acid ionic liquid and TEMPO oxidized nanocellulose to prepare the plant volatile oil. After ultraviolet radiation, the antibacterial activity is not obviously changed, and the long-acting slow-release effect is still kept in a humid environment.

Provided are a crystalline form of a pentacyclic triterpenoid compound and a preparation method of the crystalline form, the pentacyclic triterpenoid compound being 3-O-cyclohexanecarbonyl-11-carbonyl-beta-boswellic acid, abbreviated as CKBA, the preparation method of the crystalline form being simple in operation, the crystalline form prepared being more stable under light conditions, less change in impurities, and the crystalline form prepared being higher in solubility in organic solvents, lower in hygroscopicity, and more conducive to development of a subsequent preparation process. Further provided are a pharmaceutical composition using the crystalline form as an active ingredient, and use of the crystalline form in preparation of a medicament for treating psoriasis.

Topical polyherbal oleogel composition, comprising, in weight percent of the finished product: (i) Boswellia serrata CO2 select extract 1.0–5.0%; (ii) Curcuma longa phytosome 0.5–2.5% with curcuminoids complexed to phospholipids together with turmerone-rich turmeric essential oil 0.2–0.8%; (iii) Zingiber officinale CO2 select extract 0.5–2.5%; (iv) Hypericum perforatum macerate oil 3.0–10.0%; (v) Capsaicinoids in an equivalent amount of 0.01–0.05%, obtained from Capsicum oleoresin, and Mentha piperita oil 0.3–1.0% together with Rosmarinus officinalis oil 0.2–0.6%; (vi) a carrier phase of sesame oil and medium-chain triglycerides in a ratio of 2:1 to 1:1, and castor oil 8–12% and squalane 1.0–3.0%; (vii) a structuring phase of sunflower lecithin 0.8–2.0% and beeswax 3.0–6.0%, providing a lamellar, shear-thinning oleogel; and (viii) mixed tocopherols 0.1–0.3% and a rosemary diterpene antioxidant extract 0.05–0.2%;wherein the composition is anhydrous with a water activity ≤ 0.55, and wherein the mass ratio of total boswellic acids to total curcuminoids is 0.8:1 to 1.6:1 and the mass ratio of menthol to total capsaicinoids is 10:1 to 30:1.;

A composition for use in the treatment of dermatoporosis, comprising: at least one boswellic acid, optionally in the form of a plant extract in a proportion of 0.1 to 15% by weight relative to the weight of the composition, a hyaluronan in a proportion of 0.1 to 15% by weight relative to the weight of the composition, said composition further having a proportion by weight of boswellic acid to hyaluronan of between 0.5 and 2 and an excipient phase in a proportion of 99.8% to 70% by weight relative to the weight of the composition, the excipient phase being aqueous-based.

To provide a natural product-derived composition that allows for the easy intake of nutrients that can exhibit excellent functionality. [Solution] The composition comprises a collagen-containing extract derived from fish cartilage and a boswellic acid-containing extract derived from the Boswellia plant. The collagen-containing extract preferably contains type II collagen and type XI collagen, with a total mass ratio of their contents being 10:1 to 1:10, and a total content of 30% by mass or more. The boswellic acid-containing extract preferably contains 20% by mass or more of boswellic acid.

The optimized drug delivery system, with a diameter of less than 150 nm, can cross the Blood-Brain Barrier (BBB) and effectively target brain cells. This all-natural herbal formulation contains Curcumin from Turmeric and Boswellic acids from Frankincense, encapsulated in a vesicular structure. The surface of vesicular structure has been modified and optimized for maximum bioavailability. This Nanocarrier is used for prevention of Alzheimer's disease and memory enhancement. Animal studies confirmed its effectiveness, showing positive results.

Composition or association of compounds comprising: a) the active principle docosahexaenoic acid DHA (C22:6 ω-3 C22H32O2 MW 328.488) mixed with all or in part, with: b) hyaluronic acid HA4 tetrasaccharide (C28H44N2O23 MW 776) in nanoparticles c) β-caryophyllene βCP (C15H24 MW 204.35), d) furanoeudesma-1,3-diene FE (C15H18O MW 214.30), e) β-boswellic acid PBA (C30H48O3 MW 456.7). preferably for use in the treatment of nervous diseases in particular neurodegenerative diseases, method for the preparation of such composition or association of compounds and uses thereof.

The present invention deals with a composition comprising 55% w / w enriched Boswellia serrata extract containing 40% w / w total boswellic acids and 45% w / w enriched Apium graveolens L. seed extract containing 15% w / w celery bioactive (seselin and bergeptan) as quantified by HPLC, optionally along with pharmaceutically or nutraceutically acceptable excipients. The composition exhibits a synergistic effect while reducing cartilage degenerative biomarkers and increasing cartilage regenerative biomarkers when used for the treatment of osteoarthritis. The administration of the said composition also results in the reduction of pain, inflammation, and stiffness and an increase in the gap between knee joints of patients suffering from knee osteoarthritis. The methods of enrichment of extracts, preparation of said composition and treatment of subjects suffering from cartilage degeneration and osteoarthritis are described.

The present invention provides a synergistic composition comprising Boswellia- derived Frankincense oil and boswellic acid as well as methods for the synthesis of the same. Said synergistic composition comprising Frankincense oil and boswellic acid is prepared by subjecting Boswellia serrata resin gum to hydro-steam distillation process at a slightly elevated pressure, and for a short period of time, without using any organic solvents for extraction. Said synergistic composition is also prepared by combining Boswellic extract comprising at least 5 % by weight of Boswellic acid with Frankincense oil, with the combined product remaining as a clear oil, and offering the benefits of both Boswellic extract containing boswellic acid, and Frankincense oil. Said synergistic composition comprising Frankincense oil and boswellic acid is administered through topical, transdermal or oral route for the treatment of skin cancer, breast cancer, arthritis, and IBS.

The invention relates to a method for preparing high-purity 3-acetyl-11-keto-beta-boswellic acid through high-speed countercurrent chromatography separation, which comprises the following steps: by taking commercially available frankincense extract as a raw material, fully shaking a solvent system, standing for phase separation, and separately collecting an upper phase and a lower phase; dissolving the frankincense extract in the upper phase, performing separation and purification by using high-speed counter-current chromatography to obtain a mixed solution of 3-acetyl-11-keto-beta-masticinic acid and the upper phase, removing the organic solvent in the upper phase to obtain a turbid liquid containing 3-acetyl-11-keto-beta-masticinic acid, and centrifuging to remove an aqueous solution to obtain the frankincense extract. And filtering to obtain the 3-acetyl-11-keto-beta-masticinic acid. The purity of the 3-acetyl-11-keto-beta-masticinic acid prepared by the method disclosed by the invention is up to 98% or above; reagents of a solvent system can be recycled and reused, and good energy-saving and environment-friendly functions are achieved.

The invention relates to the field of traditional Chinese medicine preparations, in particular to an analgesic and anti-inflammatory patch and a preparation method thereof.The patch comprises, by weight, 30 parts of gentiana macrophylla, 15 parts of frankincense, 15 parts of myrrh, 15 parts of ligusticum wallichii, 15 parts of angelica sinensis, 10 parts of notopterygium roots, 10 parts of radix angelicae pubescentis, 10 parts of garden balsam stems, 8 parts of ground beetles, 8 parts of carthamus tinctorius, 5 parts of borneol, 3 parts of menthol and 3 parts of liquorice. The radix gentianae macrophyllae is used as a monarch drug and is matched with the medicinal materials such as the frankincense, the myrrh and the ligusticum wallichii to form a scientific and reasonable compound compatibility, the components are in synergistic interaction, and the analgesic and anti-inflammatory effects of the application are remarkably improved. Gentiana macrophylla alkali A in gentiana macrophylla and boswellic acid and gallic acid in frankincense and myrrh have a synergistic effect, cyclooxygenase can be inhibited, prostaglandin synthesis can be reduced, capillary permeability can be reduced, inflammation exudation can be relieved, and therefore the multi-target analgesic and anti-inflammatory effects are achieved.

Presently described are compositions comprising 55% w / w enriched Boswellia serrata extract containing 40% w / w total boswellic acids and 45% w / w enriched Apium graveolens L. seed extract containing 15% w / w celery bioactive (seselin and bergeptan) as quantified by HPLC, optionally along with pharmaceutically or nutraceutically acceptable excipients. The composition exhibits a synergistic effect while reducing cartilage degenerative biomarkers and increasing cartilage regenerative biomarkers when used for the treatment of osteoarthritis. The administration of the said composition also results in the reduction of pain, inflammation, and stiffness and an increase in the gap between knee joints of patients suffering from knee osteoarthritis. The methods of enrichment of extracts, preparation of said composition and treatment of subjects suffering from cartilage degeneration and osteoarthritis are described.

This invention belongs to the field of nutritional composition technology, specifically relating to a composition, composition formulation, preparation method, application, and product for improving bone health. This invention provides a composition composed of N-acetylglucosamine and 3-O-acetyl-11-keto-β-boswellic acid. The composition and formulation of this invention can promote the differentiation of chondrocyte precursor cells into mature chondrocytes, promote cartilage matrix synthesis, significantly inhibit TNF-α and MMP13 expression, and upregulate COL2A1 expression, with effects superior to single components and traditional combinations. The ingredients are natural and safe, biocompatible, and have no significant toxicity, making them suitable for people with joint noise, joint pain, osteoarthritis, and joint degeneration. Simultaneously, they can improve bone density, promote bone growth and development, and improve bone health. The preparation process is simple and low-cost, and it can be formulated into various dosage forms such as food, health products, and pharmaceuticals, offering flexible applications and combining preventative and therapeutic value.